Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed (INSM) reported an insider transaction by its Chief People Strategy Officer on 11/12/2025. The officer exercised 30,000 stock options at an exercise price of $26.46 and received common shares. On the same day, the officer sold shares in four tranches at weighted average prices of $192.45 (4,078 shares), $193.64 (6,575), $194.44 (19,183), and $195.88 (164), with ranges disclosed for each tranche. Following these transactions, the officer directly owned 36,461 common shares. Remaining derivative holdings were 15,760 options expiring on 05/12/2031, which are currently exercisable as described.
Insmed Inc. (INSM) reported insider transactions by its Chief Medical Officer on 11/11/2025. The officer exercised stock options for 12,949 shares at $17.07 and 18,277 shares at $18.95 (transaction code M), then sold shares in open-market trades (transaction code S) under a Rule 10b5-1 plan adopted on February 27, 2025.
Sales were executed at weighted average prices of $188.38 for 5,467 shares (range $187.93–$188.90), $189.36 for 12,224 shares (range $188.90–$189.88), $190.33 for 10,622 shares (range $189.92–$190.90), and $191.04 for 2,913 shares (range $190.94–$191.14). Following these transactions, the officer reported 83,111 shares beneficially owned directly. The disclosed options carry expirations on 05/11/2032 and 05/11/2033, with vesting at 25% on the first anniversary and 12.5% each six months through the fourth anniversary.
Insmed (INSM) filed a Form 4 disclosing a gift transfer by a director. On 11/06/2025, the reporting person executed a Code G transaction, gifting 60,000 shares of common stock at $0.
Following the transaction, the director held 66,933 shares directly and 60,000 shares indirectly, listed as held by spouse revocable trust. The filing indicates a change in the form of ownership, not an open-market trade.
Insmed (INSM) reported an insider transaction by its Chief Legal Officer. On 11/03/2025, the officer exercised 27,130 stock options at an exercise price of $23.75 and sold shares in multiple tranches under a Rule 10b5-1 trading plan adopted on February 27, 2025.
The sales were executed at weighted average prices ranging from $181.01 to $187.97, with the filing noting price ranges and an undertaking to provide per-price breakdowns upon request. Following the reported transactions, the officer beneficially owned 54,902 shares directly.
Insmed Incorporated reported Q3 2025 results with product revenues, net of $142,342, up from $93,425 a year ago. ARIKAYCE delivered $114,291 (US $73,984; International $40,307), and the newly approved BRINSUPRI contributed $28,051 in its US launch quarter. Operating expenses rose sharply, including a $104,653 increase in the fair value of contingent consideration, leading to an operating loss of $366,005 and a net loss of $370,021. Basic and diluted net loss per share was $1.75 on 211,759 thousand weighted average shares.
Liquidity and capital structure shifted meaningfully. Cash and cash equivalents were $334,764 and marketable securities were $1,345,222 as of September 30, 2025. Long-term debt declined to $539,719 from $1,103,382 as the 0.75% 2028 notes were largely converted and then redeemed, while an amended senior term loan now carries a fixed 9.6% rate and matures in 2029. Shares outstanding were 212,583,015 as of September 30, 2025.
Pipeline and commercialization updates included FDA approval of BRINSUPRI on August 12, 2025 and continued global sales of ARIKAYCE. For the nine months ended September 30, 2025, product revenues, net were $342,580 versus $259,265, while operating cash use was $687,418, reflecting heavier R&D and SG&A to support launches and development.
Insmed Incorporated announced it has furnished a press release detailing its financial results for the third quarter ended September 30, 2025. The company also provided a slide presentation to accompany its conference call.
Both materials are included as Exhibits 99.1 and 99.2. The information is furnished under Item 2.02 and Item 9.01 and is not deemed “filed” for purposes of Section 18 of the Exchange Act.
INSMED Inc (INSM) reporting person S. Nicole Schaeffer, Chief People Strategy Officer, completed multiple transactions on 09/12/2025 under a 10b5-1 plan. She exercised 56,520 stock options with a $23.75 exercise price, resulting in ownership of 56,520 shares from the exercise and a reported pre-sale beneficial ownership of 112,981 shares. On the same date she sold a total of 76,520 shares in four separate sell transactions at weighted average prices of $144.6, $145.67, $146.57, and $147.46, leaving her with 36,461 shares beneficially owned following the reported transactions. The sales were effected pursuant to a 10b5-1 trading plan adopted June 13, 2025, and the filing is signed by an attorney-in-fact on behalf of the reporting person.
Melvin Sharoky, M.D., a director of INSMED Inc (INSM), reported multiple transactions on Form 4 reflecting gifts and a market sale. The filing shows gift transactions (Code G) and a sale of 10,000 shares on 09/12/2025 at a weighted average price of $145.39 per share. Following the reported sale and other transactions, the reporting person directly beneficially owns 262,675 shares. The report also discloses indirect holdings through entities Baby Gator LLC and Padonia, LLC and multiple custodial UTMA accounts where the reporting person is custodian.
Insmed, Inc. (INSM) reporting person S. Nicole Schaeffer, Chief People Strategy Officer and director, reported a non-derivative disposition on 09/04/2025. The filing shows a gift (Transaction Code G) of 23,303 common shares at a price of $0, leaving 56,461 shares beneficially owned directly after the transaction. No derivative transactions were reported. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Insmed, Inc. (INSM) Chief Legal Officer Michael A. Smith reported transactions on 09/02/2025. Mr. Smith exercised stock options to acquire 12,780 shares at an exercise price of $30.46 and immediately sold multiple blocks of common stock under a Rule 10b5-1 trading plan. The sales totaled 24,252 shares at weighted average prices ranging from $140.58 to $146.04 per share, reducing his reported beneficial ownership from 79,174 shares to 54,902 shares. All exercised options are currently exercisable and the transactions were effected pursuant to a 10b5-1 plan adopted February 27, 2025.